A novel ultra-sensitive enzyme immunoassay for soluble human insulin receptor ectodomain and its measurement in urine from healthy subjects and patients with diabetes mellitus

Clinical Biochemistry

Volumn 42, Issue 13-14, 2009, Pages 1468-1475

  Umehara, Asako ^a   Nishioka, Mamiko ^a   Obata, Toshiyuki ^b   Ebina, Yousuke ^c   Shiota, Hiroshi ^c   Hashida, Seiichi ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Diabetes; Enzyme immunoassay; Insulin; Insulin receptor; Leptin; Resistin; Urine

Indexed keywords

CREATININE; GLUCOSE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR ALPHA; LEPTIN; RESISTIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; NON INVASIVE PROCEDURE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; URINALYSIS;

ADOLESCENT; ADULT; ANTIGENS, CD; BINDING SITES; BLOOD GLUCOSE; CALIBRATION; CIRCADIAN RHYTHM; DIABETES MELLITUS; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN; LEPTIN; MALE; MIDDLE AGED; OBESITY; RECEPTOR, INSULIN; REPRODUCIBILITY OF RESULTS; RESISTIN; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 69249220091     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.06.014     Document Type: Article

References (23)

1. Zimmet P., Alberti K.G.M.M., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787
2. Wild S., Sicree R., Roglic G., King H., and Green A. Global prevalence of diabetes. Diab. Care 27 (2004) 1047-1053
3. Tahara Y., and Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. Diabetes Care 18 (1995) 440-447
4. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diab. Res. Clin. Pract. 28 (1995) 103-117
5. Edelman D., Olsen M.K., Dudley T.K., Harris M.C., and Oddone E.Z. Utility of hemoglobin A1c in predicting diabetes risk. J. Gen. Intern. Med. 19 (2004) 1175-1180
6. Ko G.T., Chan J.C., Tsang L.W., and Cockram C.S. Combined use of fasting plasma glucose and HbA1c predicts the progression to diabetes in Chinese subjects. Diabetes Care 23 (2000) 1770-1773
7. Norberg M., Eriksson J.W., Lindahl B., et al. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed. J. Intern. Med. 260 (2006) 263-271
8. Inoue K., Matsumoto M., and Kobayashi Y. The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese worker. Diab. Res. Clin. Pract. 77 (2007) 451-458
9. Inaba M., Okuno S., Kumeda Y., et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J. Am. Soc. Nephrol. 18 (2007) 896-903
10. Davidson M.B., Schriger D.L., and Lorber B. HbA(1c) measurements do not improve the detection of type 2 diabetes in a randomly selected population. Diabetes Care 24 (2001) 2017-2018
11. Perry R.C., Shankar R.R., Fineberg N., McGill J., and Baron A.D. HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP). Diabetes Care 24 (2001) 265-271
12. Pezzino V., Papa V., Costantino A., et al. Identification and initial characterization of insulin receptor-like immunoreactivity in human plasma. J. Clin. Endocrinol. Metab. 74 (1992) 1116-1121
13. Obata T., Yokota I., Yokoyama K., et al. Soluble insulin receptor ectodomain is elevated in the plasma of patients with diabetes. Diabetes 56 (2007) 2028-2035
14. Ishikawa E., Imagawa M., Hashida S., Yoshitake S., Hamaguchi Y., and Ueno T. Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. J. Immunoassay 4 (1983) 209-227
15. Hashida S., and Ishikawa E. Detection of one milliattomole of ferritin by novel and ultrasensitive enzyme immunoassay. J. Biochem. 108 (1990) 960-964
16. Hashida S., Hashinaka K., and Ishikawa E. Ultrasensitive enzyme immunoassay. In: EI-Gewely M.R. (Ed). Biotechnology annual review Vol. 1 (1995), Elsevier Science B.V., Amsterdam p403-51
17. Hashida S., Kitamura K., Nagatomo Y., et al. Development of an ultra-sensitive enzyme immunoassay for human proadrenomedullin N-terminal 20 peptide (PAMP) and direct measurement of two molecular forms of PAMP in plasma from healthy subjects and patients with cardiovascular disease. Clin. Biochem. 37 (2004) 14-21
18. Hashida S., Ishikawa E., Kato Y., Imura H., Mohri Z., and Murakami Y. Human growth hormone (hGH) in urine and its correlation to serum hGH examined by a highly sensitive sandwich enzyme immunoassay. Clin. Chim. Acta 162 (1987) 229-235
19. Sukegawa I., Hizuka N., Takano K., et al. Urinary growth hormone (GH) measurements are useful for evaluating endogenous GH secretion. J. Clin. Endocrinol. Metab. 66 (1988) 1119-1123
20. Meyer C., Robson D., Rackovsky N., Nadkarni V., and Gerich J. Role of the kidney in human leptin metabolism. Am. J. Physiol. 273 (1997) E903-E907
21. Klein S., Coppack S.W., Mohamed-Ali V., and Landt M. Adiposetissue leptin production and plasma leptin kinetics in humans. Diabetes 45 (1996) 984-987
22. Merabet E., Dagogo-Jack S., Coyne D.W., et al. Increased plasma leptin concentration in end-stage renal disease. J. Clin. Endocrinol. Metab. 82 (1997) 847-850
23. Zaman N., Hall C.M., Gill M.S., et al. Leptin measurement in urine in children and its relationship to other growth peptides in serum and urine. Clin. Endocrinol. 58 (2003) 78-85